Somerson Jeremy S, Matsen Frederick A
The University of Texas Medical Branch, Galveston, Texas.
Department of Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington.
J Bone Joint Surg Am. 2017 Dec 6;99(23):1999-2003. doi: 10.2106/JBJS.17.00201.
We previously reported the results at an average of 4.5 years after treatment of 176 patients with the ream-and-run arthroplasty. In the present study, we present the patient self-reported functional outcomes and clinical implant survival of the original cohort at a mean of 10 years (range, 5 to 16 years). Twenty-eight (16%) of the 176 patients had a subsequent procedure, 11 (6%) died, and 30 (17%) had <5 years of follow-up. The Simple Shoulder Test (SST) score at the time of the latest follow-up was a median of 11 points (interquartile range, 9 to 12 points) and a mean (and standard deviation) of 10 ± 2.6 points, out of a possible 12 points. The present study demonstrates that the improvement in function and comfort derived from the ream-and-run procedure can be sustained at the time of mid-term follow-up.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
我们之前报告了176例行扩髓-锉髓术治疗患者平均4.5年的治疗结果。在本研究中，我们展示了该初始队列患者平均10年（范围5至16年）的自我报告功能结局和临床植入物生存率。176例患者中有28例（16%）接受了后续手术，11例（6%）死亡，30例（17%）随访时间不足5年。最新随访时简易肩关节测试（SST）评分中位数为11分（四分位间距9至12分），在可能的12分中平均（及标准差）为10±2.6分。本研究表明，扩髓-锉髓术带来的功能和舒适度改善在中期随访时可得以维持。
治疗性IV级。有关证据水平的完整描述，请参阅《作者须知》。
